Douglas Tsao

Stacy Ku

Chase Knickerbocker

Roanna Clarissa Ruiz

Christian Clark

Glen Santangelo

Jason McCarthy

Naz Rahman

- **scPharmaceuticals Inc. (SCPH)** was **acquired by MannKind Corporation** on **October 7, 2025**, becoming a **direct wholly owned subsidiary**.  **[1604950_0001193125-25-232754_d20686d8k.htm:3]** **[1604950_0001193125-25-232754_d20686d8k.htm:6]** 
- Shareholders received **$5.35 in cash** and one non-tradable **contingent value right (CVR)** per share, with CVRs potentially yielding up to an additional **$1.00**.  **[1604950_0001193125-25-232754_d20686d8k.htm:1]** **[1604950_0001193125-25-232754_d20686d8k.htm:3]** 
- Following the acquisition, SCPH shares were **delisted from The Nasdaq Global Select Market**, and trading was halted on **October 7, 2025**.  **[1604950_0001193125-25-232754_d20686d8k.htm:5]** 
- The company's **Board of Directors resigned**, and a new management team was appointed, including **Michael E. Castagna** as President and Chief Executive Officer, and **Chris Prentiss** as Chief Financial Officer of the surviving corporation.  **[1604950_0001193125-25-232754_d20686d8k.htm:6]** 
- Key agreements, including the **Credit Agreement and Guaranty** and the **Revenue Participation Right Purchase and Sale Agreement**, were terminated in connection with the merger.  **[1604950_0001193125-25-232754_d20686d8k.htm:2]**

scPharmaceuticals Inc. Acquired by MannKind Corporation

- MannKind Corporation completed the acquisition of scPharmaceuticals Inc. on **October 7, 2025**, making scPharmaceuticals a **wholly owned subsidiary**.  **[1604950_fbee13d4ebfe483eb1aaf4c7eb1b2174_0]** **[1604950_fbee13d4ebfe483eb1aaf4c7eb1b2174_1]** 
- The acquisition is expected to **diversify and accelerate MannKind’s double-digit revenue growth**, driven by the innovative therapy **FUROSCIX®**.  **[1604950_fbee13d4ebfe483eb1aaf4c7eb1b2174_0]** 
- The transaction was valued at **$5.35 per share in cash** plus one non-tradable contingent value right (CVR) per share for up to an aggregate of **$1.00 per CVR** in cash, totaling up to **$6.35 per share**.  **[1604950_fbee13d4ebfe483eb1aaf4c7eb1b2174_0]** 
- As of **October 7, 2025**, scPharmaceuticals' common stock **ceased trading and was delisted from Nasdaq**.  **[1604950_fbee13d4ebfe483eb1aaf4c7eb1b2174_1]**

scPharmaceuticals Acquisition by MannKind Completed

- Halper Sadeh LLC is investigating **scPharmaceuticals Inc. (NASDAQ: SCPH)** for potential violations of federal securities laws and/or breaches of fiduciary duties to shareholders.  **[1604950_20250916NY74747:0]** 
- The investigation relates to scPharmaceuticals Inc.'s proposed sale to MannKind Corporation.  **[1604950_20250916NY74747:0]** 
- Under the terms of the proposed transaction, scPharmaceuticals shareholders would receive a cash payment of **$5.35 per share** plus one non-tradable contingent value right (CVR) per share, with the CVR potentially worth up to an additional **$1.00** in cash.  **[1604950_20250916NY74747:0]**

scPharmaceuticals (SCPH)